Nanotherapeutic strategies for mitigating sepsis-induced multiorgan dysfunctions

One of the biggest causes of morbidity and mortality in the world today is sepsis, primarily due to dysregulated host responses that culminate in systemic inflammation, oxidative stress, and progressive multi-organ failure. Conventional therapeutics are limited by poor pharmacokinetics, inadequate organ-specific delivery, rapid systemic clearance, and dose-limiting toxicity. Nanotechnology offers promising solutions by improving drug stability, enhancing bioavailability, and enabling targeted and controlled delivery to affected organs. Advances in nanocarrier engineering, including liposomes, polymeric nanoparticles, lipid-based systems, inorganic nanomaterials, and hybrid platform,s have enabled modulation of immune pathways, attanuates inflammatory cascades, bacterial toxins, and scavenging of excessive reactive oxygen species implicated in sepsis progression. Furthermore, organ-targeted and stimuli-responsive nanosystems have demonstrated potential to selectively accumulate in injured kidneys, lungs, liver, spleen, and the brain, thereby improving therapeutic index and reducing off-target effects. Emerging smart nanocarriers provide spatiotemporal release in response to disease-specific microenvironmental cues such as pH, enzymes, and oxidative species. This review summarizes current progress in nano-enabled therapeutic strategies for sepsis-induced acute organ injuries, discusses targeting mechanisms and delivery platforms, and highlights translational advancements and remaining barriers toward clinical adoption. Nanotechnology-based interventions represent a transformative approach with potential to redefine treatment paradigms in sepsis and associated organ failure.